


DIABETES

1978年7月1日



DIABETES

PROCEEDINGS OF THE EIGHTH CONGRESS
OF THE INTERNATIONAL DIABETES FEDERATION

Brussels, July 15-20, 1973

EDITORS

W. J. MALAISSE

Brussels

J. PIRART

Brussels

CO-EDITOR

J. VALLANCE-OWEN

Belfast



1974

EXCERPTA MEDICA, AMSTERDAM

AMERICAN ELSEVIER PUBLISHING COMPANY, INC., NEW YORK

© EXCERPTA MEDICA, 1974

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

INTERNATIONAL CONGRESS SERIES No. 312

ISBN EXCERPTA MEDICA 90 219 0235 4

ISBN AMERICAN ELSEVIER 0 444 15074 9

LIBRARY OF CONGRESS CATALOG CARD NUMBER 74-77386

Publisher:

EXCERPTA MEDICA
335 Jan van Galenstraat
Amsterdam
P.O. Box 1126

Sole Distributors for the USA and Canada:

AMERICAN ELSEVIER PUBLISHING COMPANY, INC.
52 Vanderbilt Avenue
New York, N.Y. 10017

Printed in The Netherlands by Casparie Alkmaar B.V.

TABLE OF CONTENTS

PLENARY LECTURES

P. A. BASTENIE: Immunity, autoimmunity, and diabetes	3
A. E. RENOLD, A. RABINOVITCH, C. B. WOLLHEIM, M. KIKUCHI, A. H. GUTZEIT, M. AMHERDT, F. MALAISSE-LAGAE and L. ORCI: Spontaneous and experimen- tal diabetic syndromes in animals. A re-evaluation of their usefulness for ap- proaching the physiopathology of diabetes	22
R. LUFT: Clinical research on the molecular level	39
G. F. CAHILL JR.: Diabetes, insulin and future developments	53

PANELS

BETA CELL 1973

B. HELLMAN, L.-Å. IDAHL, Å. LERNMARK, J. SEHLIN and I.-B. TÄLJEDAL: Mem- brane sulphhydryl groups and the pancreatic beta cell recognition of insulin se- cretagogues	65
A. E. LAMBERT, J.-C. HENQUIN and L. ORCI: Role of beta cell membrane in in- sulin secretion	79
W. J. MALAISSE and D. G. PIPELEERS: The role of cations in insulin synthesis and release	95
L. ORCI, M. RAVAZZOLA, M. AMHERDT and F. MALAISSE-LAGAE: The B cell boundary	104
D. F. STEINER, J. D. PETERSON, H. S. TAGER, S. O. EMDIN, Y. OSTBERG and S. FALKMER: Comparative aspects of proinsulin and insulin structure and bio- synthesis	119

THE ROLE OF GLUCAGON IN HEALTH AND DIABETES

R. H. UNGER: New aspects of glucagon pathology and pathophysiology	137
R. ASSAN, J. R. ATTALI, G. BALLERIO, J. R. GIRARD, M. HAUTECOUVERTURE, A. KERVAN, P. F. PLOUIN, G. SLAMA, E. SOUFFLET, G. TCHOBROUTSKY and A. TIENGO: Some aspects of the physiology of glucagon	144
L. G. HEDING: Hypoglucagonemic states	180
A. LUYCKX and P. LEFEBVRE: The role of energy substrates in controlling gluca- gon secretion. Experimental studies	190
S. PEK: Effect of enteric factors on pancreatic alpha cell function	203
S. PEK, S. S. FAJANS, J. C. FLOYD JR. and R. F. KNOPE: Clinical conditions asso- ciated with elevated plasma levels of glucagon	207

REGULATION OF METABOLIC FUELS SUPPLY

P. FELIG and J. WAHREN: Amino acids and gluconeogenesis: influence of blood cells, obesity, prolonged exercise, and glucocorticoids	217
E. O. BALASSE: Interactions of insulin, ketone bodies and free fatty acids in the regulation of peripheral utilization of substrates	231
E. B. MARLISS and J. R. GIRARD: Glucagon regulation of metabolic fuel supply	241

TABLE OF CONTENTS

M. VRANIC and A. CHERRINGTON: The regulation of glucose turnover (mobilization and supply) and FFA concentration by insulin-glucagon interaction in dogs	256
D. H. WILLIAMSON: Control of hepatic ketogenesis in vivo. The present position	271
INSULITIS AND VIRUS	
W. GEPTS: Insulitis and viruses. Introductory remarks	285
J. E. CRAIGHEAD: Viral lesions of the pancreatic islets of Langerhans	287
G. FREYTAG and G. KLÖPPEL: Immune insulitis, comparison with viral insulitis	292
G. M. GRODSKY, B. FRANKEL, A. RUDNICK, J. SCHACHTER, J. LEE, R. FANSKA and L. WEST: Characteristics of M-variant encephalomyocarditis virus (EMC) in the chemically diabetic non-obese chinese hamster	304
H. MÜNTEFERING: Ultrastructure of viral insulitis	316
D. R. GAMBLE, T. J. COLEMAN and K. W. TAYLOR: Epidemiological and experimental studies in relation to Cocksackie viruses as an aetiological factor in diabetes	321
NATURAL HISTORY AND PREVENTION OF DIABETES	
S. S. FAJANS, C. I. TAYLOR, J. C. FLOYD JR. and J. W. CONN: Some aspects of the natural history of diabetes mellitus	329
E. CERASI: Metabolic consequences of low insulin response in non-diabetic subjects	341
D. L. RIMOIN: Genetics of diabetes mellitus	346
LIPID DISORDERS AND DIABETES	
R. J. HAVEL: Lipid transport and insulin resistance	353
E. L. BIERMAN: Insulin levels and plasma triglyceride removal in diabetes	360
J. BOBERG, B. FURBERG and H. HEDSTRAND: Indices of lipid transport and serum insulin in patients with asymptomatic glucose intolerance	365
E. A. NIKKILÄ: Plasma triglyceride metabolism in relation to insulin secretion in man	371
S. SAILER: Indices of carbohydrate metabolism in patients with endogenous hypertriglyceridemia	381
BIOCHEMISTRY AND STRUCTURE OF DEGENERATIVE LESIONS IN DIABETES	
A. I. WINEGRAD, A. D. MORRISON and R. S. CLEMENTS JR.: The polyol pathway: A model for biochemical mechanisms by which hyperglycemia may contribute to the pathogenesis of the complications of diabetes mellitus	387
E. RASIO, M. BENDAYAN and E. B. SANDBORN: Ultrastructure and glucose metabolism of an isolated blood capillary preparation	396
R. G. SPIRO: Renal glomerular basement membrane subunits	411
J. D. WARD: Structure and biochemistry of degenerative lesions in diabetes mellitus. Pathogenesis of diabetic neuropathy	419
J. R. WILLIAMSON, N. VOGLER and C. KILO: The natural history of basement membrane disease in diabetes mellitus	424

TABLE OF CONTENTS

DIABETIC RETINOPATHY: NATURAL HISTORY, PATHOLOGY AND THERAPY

R. FRASER, E. M. KOHNER, G. F. JOPLIN, F. H. DOYLE, A. M. HAMILTON and R. K. BLACH: The place and the effect of pituitary ablation for diabetic retinopathy	431
M. D. DAVIS, F. L. MYERS, R. L. ENGERMAN, G. DE VENECIA and G. H. BRESNICK: Diabetic retinopathy — Natural course	439
C. T. DOLLERY and E. M. KOHNER: The contribution of fluorescence angiography to the understanding of diabetic retinopathy	443
P. HENKIND: Diabetic retinopathy: Pathology	448
H.-W. LARSEN: Assessment of the severity of diabetic retinopathy in relation to morphological fundus changes and visual disturbances	455

THE FETO-MATERNAL UNIT IN DIABETES

J. J. HOET: Introductory remarks	465
R. A. CHEZ and D. H. MINTZ: A monkey model of human pregnancy complicated by glucose intolerance	468
N. FREINKEL, B. E. METZGER, M. NITZAN, R. DANIEL, B. Z. SURMACZYNSKA and T. C. NAGEL: Facilitated anabolism in late pregnancy: some novel maternal compensations for accelerated starvation	474
S. GRASSO, A. MESSINA, G. DISTEFANO, R. VIGO and G. REITANO: Regulation of insulin and HGH secretion in the premature infant	489
L. MØLSTED-PEDERSEN and J. PEDERSEN: Interrelationship of birth weight with K value and plasma insulin secretion pattern in newborn infants with erythroblastosis fetalis. A comparison with infants of normal and of diabetic mothers	499

JUVENILE DIABETES, TOTAL DIABETES, BRITTLE DIABETES

P. H. WRIGHT: Experimental models for the study of juvenile diabetes	509
R. L. JACKSON: Juvenile diabetes	520
J. MIROUZE and F. COLLARD: Continuous blood glucose monitoring in brittle diabetes	532
G. D. MOLNAR: Unstable diabetes: concepts of its nature and treatment based on continuous blood glucose monitoring studies	546

SHORT- AND LONG-TERM EFFECTS OF ORAL HYPOGLYCEMIC AGENTS

E. F. PFEIFFER: Sulfonylureas: newer aspects of pharmacology and clinical efficacy	563
R. FELDMAN, D. CRAWFORD, R. ELASHOFF and A. GLASS: Oral hypoglycemic drug prophylaxis in asymptomatic diabetes	574
H. KEEN, R. J. JARRETT and J. H. FULLER: Tolbutamide and arterial disease in borderline diabetics	588
H. MEHNERT: The biguanides: mechanism of action and clinical application	603
T. E. PROUT: Adverse effects of the oral hypoglycemic drugs	612

WHAT TO AIM AT IN THE TREATMENT OF DIABETES?

J. B. FIELD: What to aim at in the treatment of diabetes	627
W. P. U. JACKSON: Diagnosis and dietary management of mild, obese and borderline diabetics	639

TABLE OF CONTENTS

L. P. KRALL: Goals of treatment and why they are not achieved	645
K. LUNDBAEK: Quantitative studies of diabetic nephropathy and the growth hormone hypothesis	657
G. TCHOBROUTSKY: How to achieve better diabetic control? Studies with insulin three times a day	667

NEW DATA ON ISLET CELL TUMORS

W. CREUTZFELDT, R. ARNOLD, C. CREUTZFELDT, H. FRERICHS and N. S. TRACK: Morphological and biochemical investigations in human insulinomas and gastrinomas	683
S. BONFILS: New data on non-B cell tumors of the pancreas	703
L. E. BRODER and S. K. CARTER: Chemotherapy of malignant insulinomas with streptozotocin	714
C. HEDINGER: Origin and morphology of islet cell tumors with single or multiple hormone production	728
A. H. RUBENSTEIN, M. E. MAKO, J. I. STARR, D. J. JUHN and D. L. HORWITZ: Circulating proinsulin in patients with islet cell tumors	736
Index of authors	753
Subject Index	755

PLENARY LECTURES

IMMUNITY, AUTOIMMUNITY, AND DIABETES*

P. A. BASTENIE

Laboratoire de Médecine Expérimentale, Université de Bruxelles, Belgique

It is easily thought, said and even written that diabetes mellitus, like other conditions of ill-defined etiology, may be (some say is) an autoimmune disease. Such a definite statement might correspond to some sort of fashionable thinking, rather than to a critical evaluation of proved facts. As professor Heremans (1973) recently said: 'Immunology is like a fungus the mycelium of which pervades the whole dignified building of medicine, suddenly producing crops of mushroom in areas where its presence was least expected, for instance endocrinology'. As far as diabetes is concerned, one may still wonder about the quality of this mushroom. To ascertain this, it seemed necessary to bring together not only diabetologists and pathologists interested in the subject but also, and foremost, basic immunologists. Thanks to the generous support of the Francqui Foundation, such a meeting was organized a few months ago by doctor Willy Gepts and myself. For the greater part of this talk I shall only be the spokesman of the distinguished participants of this Colloquium. However, I shall have to accept the responsibility for most of the conclusions and final considerations.

This review will be divided into 3 parts:

1. The initial, already 10 years old, concept of autoimmunity, on which the assumption is based that diabetes mellitus in itself is an autoimmune disease.
2. The present concepts of autoimmunity.
3. The discussion, on the basis of these concepts, of the data which argue in favour of autoimmune processes playing a part in the pathology of diabetes mellitus.

THE INITIAL CONCEPTS OF AUTOIMMUNITY

Autoimmune diseases entered medical thinking only 17 years ago when Roitt et al. (1956) discovered the presence of thyroid antibodies in the serum of patients affected with Hashimoto's goiter while Rose and Witebsky (1956) produced lymphocytic thyroiditis in the experimental animal by injecting homologous thyroglobulin. Some time afterwards autoimmunity was defined as a condition in which 'structural or functional damage is produced by the action of immunologically competent cells or antibodies against normal components of the body' (Mackay and Burnet, 1963).

It was then proposed to separate such conditions into 2 distinct groups: the acquired

* Presidential Address.

TABLE 1
Secondary, acquired or transient autoimmune diseases

Syndrome	Tissue affected	Induced by
Dressler	Pericardium Myocardium	Necrosis Virus Trauma
Endophthalmitis	Lens	Infection Trauma
Hemolytic anemia	Red cells	Ovarian tumor Lymphoma Mononucleosis infection
Male sterility	Testicles	Stasis in vas deferens

or transient and the idiopathic diseases. In the first group (Table 1) the pathological process was recognized as the result of a primary anomaly arising in the tissues. Despite the normal working of the immune system, assuring tolerance of all the body components, the abnormal antigen admittedly induced an autoimmune reaction, i.e., an immune reaction against a tissue component of the body itself. Peri- and myocarditis, arising after myocardial damage by viral attack, surgery or infarct, is the best example of such a condition.

The second group, that of idiopathic diseases (Table 2), includes several conditions which are often associated. Here organ-specific autoimmunity and tissue damage are supposed to be related to the spontaneous loss of the normal tolerance of these tissue components. This loss of tolerance was thought to be due to a sudden abnormality arising within the immune system, i.e., proliferations of immunologically competent cells active against certain constituents of the body. Normally such forbidden clones should have been eliminated once and for all during fetal life (Burnet, 1959a, b; Mackay and Burnet, 1963).

According to criteria set forth by Witebsky, Feltkamp (1966) and others, idiopathic autoimmune diseases have a series of common characteristics (Table 3): the serum contains specific antibodies and thus increased levels of IgG. In the tissues one finds destructive cell lesions and characteristic lymphocytes and plasma cells infiltrations. Moreover, similar lesions can be reproduced by injecting in the experimental animal extracts of its own tissues. On the clinical side, one finds that these autoimmune diseases are more frequent in women than in men and that their incidence increases with age.

Another important trait is the occurrence in the patients thus affected of other so-called autoimmune diseases or at least of antibodies pertaining to these diseases. Among

TABLE 2
Idiopathic autoimmune diseases

Tissue or organ affected	Disease
Blood	Idiopathic hemolytic anemia Idiopathic thrombocytopenia
Collagen	Rheumatoid arthritis Lupus erythematosus diffusus etc.
Thymus	Myasthenia gravis
<u>Gastric mucosa</u>	<u>Pernicious anemia</u>
<u>Adrenal cortex</u>	<u>Addison's disease</u>
<u>Thyroid</u>	<u>Thyroiditis and hypothyroidism</u>

the close relatives of such patients one finds a high incidence of: (1) the same disease; (2) antibodies characteristic of that disease; and (3) other autoimmune diseases. The best example of this pathology is autoimmune thyroiditis, leading to spontaneous myxedema. All stages have now been studied from normality to asymptomatic thyroiditis and to clinical hypothyroidism (Bastenie et al., 1972a). Not only the morphological changes in the thyroid and in the pituitary induced by the progressive thyroiditis and parenchyme destruction, but all criteria set forth for idiopathic autoimmune diseases are fulfilled (Feltkamp, 1966).

How far does diabetes mellitus conform to these criteria? Admittedly the overall incidence of diabetes is highest in women and increases with age (Table 4). Insulinitis has been described, albeit almost exclusively in juvenile diabetics. Insulinitis has been reproduced experimentally and in a few animals has led to the development of diabetes. Moreover, the association of diabetes with other autoimmune diseases has repeatedly been shown, mostly with thyroiditis. Diabetes itself runs in families.

It is easy to understand that many are inclined to include diabetes among the idiopathic autoimmune diseases.

THE PRESENT CONCEPTS OF IMMUNITY AND AUTOIMMUNITY

The new knowledge which has upset this assumption results from the shifting of the study of antibodies to that of the cellular reactions to the antigens. Only recently was delayed hypersensitivity (i.e. specific cell-mediated immunity) considered in the pathogenesis of human autoimmune disorders. The mobilization of cellular defenses was first studied in experimental autoimmunity in the rejection of homografts. These studies have led to the already classical knowledge concerning the cellular basis of immune responses as reviewed by Roitt et al. (1969).

TABLE 3
Characteristics of idiopathic autoimmune diseases (AID)

Serum	Antibodies: IgG ↑ Complement ↓
Tissues	Parenchyme destruction Lymphoblastomatocytes infiltrations
Experimental reproduction	Tissue lesions Antibodies
Clinic	F > M ↑ with age
Associations	In patient: other AID antibodies In close relatives: same AID other AID antibodies

TABLE 4
Diabetes mellitus as an idiopathic AID

Criteria of AID	Diabetes
F > M	+
Incidence ↑ with age	+
Lymphocytic infiltrates	+
Experimental production	+
Association-other AID	+
Association in close relatives	+
Diabetes; other AID	+
Antibodies in serum IgG ↑	0?

IMMUNITY, AUTOIMMUNITY, AND DIABETES

The small lymphocytes belong to 2 distinct populations: one dependent on the presence of the thymus and therefore called T lymphocytes and the other independent of the thymus and originating from the bone marrow, called B lymphocytes. The T lymphocytes constitute the greater part of the small lymphocytes circulating in the blood. B lymphocytes appear to be more restricted to lymphoid tissue:

The T lymphocytes can be non-specifically stimulated in cultures by phytohemagglutinin, a non-specific mitogen which acts on other receptor sites besides those which are antigen-sensitive. This response to non-specific mitogens provides some measure of the overall activity of T lymphocytes in the blood but need not necessarily reflect their ability to react to specific antigens (Fudenberg et al., 1971).

The small T lymphocytes can also be stimulated into blast cells by the action of an antigen, which has been processed by the action of macrophages and thereby transformed into an immunogen. The clones of cells which stem from the immunogen-stimulated T lymphocytes will differentiate into 'killer cells'. The effects of these cells have been well studied in graft rejections, in human thyroiditis and in tissue cultures of Hashimoto goitre.

The immunogen-stimulated T lymphocytes further secrete soluble factors which have several properties: distention and increased permeability of the capillaries, and stimulation or inhibition of macrophages. There is further evidence that the immunogen-stimulated T cells can cooperate with the B cells and control their activity (Allison et al., 1971).

The B cells, stimulated by an immunogen (transformed antigen) can also differentiate into blast cells which will produce cell clones resulting in the formation of plasmacytes. These specialized cells are the seat of synthesis and secretion of specific antibodies. It is now clear that the production of antibodies, important as it may be in certain cases (as for instance in hemolytic anemia), is in many cases of little direct pathogenic significance. The antibodies may, however, stimulate inactive tolerant T lymphocytes into immune reactions (cf. Heremans, 1973).

Research has now turned to the study of the action of antigens in calling forth the reactions of immunocytes and to the study of these reactions in order to explain the disappearance of the normal state of tolerance, which the immunocytes normally display




FIG. 1. Epitopes of antigens (after Heremans, 1973).

towards the various components of 'self'. Antigens are considered as possessing epitopes (Fig. 1), which are the immunogenic sites directed against T or B lymphocytes and are therefore called t or b epitopes. These epitopes are composed of proteins, polysaccharides or nucleic acids. Many epitopes are normally hidden and are brought to light only after partial enzymatic breakdown or denaturation (i.e. uncoiling) of the macromolecule.

Even resting immunocytes exhibit a low level of immunoglobulin synthesis. A fraction of this immunoglobulin is incorporated into their cell membrane, where it stays for a period of hours before being lost (Fig. 2). The combination on these receptor sites of the




FIG. 2. Schematic representation of an immunocyte.

immunoglobulin with the antigen can be observed in autoradiographic preparations seen in electron microscopy: when the antigen is marked with radioiodine, it impresses a silver reagent. The black dots which then appear on the cellular membrane are the results of the combination with the Ag on the receptor sites. Such a combination may result in: (1) induction of immune reactions; and (2) inhibition of immune reactions.

The first possibility has already been discussed. In the second possibility the immunocyte fails to undergo induction and becomes refractory to subsequent stimulation: the antigen has behaved as a tolerogen. In other words: immunocytes may become tolerant to antigens which in other circumstances might induce immune reactions. They do so when submitted to excess stimulation; cells so impressed will die or become inactive. However, tolerance is maintained only in so far as the supply of antigen is kept up.

T and B cells do not react in the same way nor to the same antigens. T tolerance is faster in onset, more protracted and obtained with lower concentrations. Therefore T lymphocytes are tolerant to normal self-antigens which are present in low concentrations in the circulating blood. Moreover, according to many observations in vivo (see Heremans, 1973), T cells are necessary both for induction of immune responses and for immune tolerance. They effect these actions by the secretion of associative antibodies. This is shown experimentally since transfers of thymus cells from young to old mice reduce the incidence of autoimmune manifestations.

Tolerance to self-antigens thus appears as an intricate process, which must continuously be acquired, renewed and maintained (Fig. 3). In the concept of balanced self-tolerance, proposed by Heremans, self-antigens present in small quantities in the serum

IMMUNITY, AUTOIMMUNITY, AND DIABETES




FIG. 3. The concept of balanced self-tolerance in the normal state (Heremans, 1973).

would partly activate the inactive T cells (Ti) and B cells (Bi) so that some slight degree of antibody formation would be produced. However, this autoimmune reaction eliminates part of antigen, and on the other hand the auto-antibodies exert a negative feed-back on the production of antibodies. Thus in the normal state self-antigens and autoimmune reactions at every moment neutralize each other as in a kind of treadmill. Autoimmunity results from the break-down of this balance, which can be due to changes in the quality or the quantity of the self-antigens — or to an alteration in the immune system — often an immune deficiency, cellular or humoral (Table 5).

TABLE 5
Breakdown of tolerance of self-antigens

Factors affecting	— antibody forming cells
	— cell mediated immune reactions
Defect of control mechanism	— genetic
	— acquired
Altered antigens	— chemical drugs
	— infections (viral)
	— metabolic processes
	— cell death

An important byproduct of the experimental work just reviewed consists of a series of tests of cell-mediated immunity that can now be applied to clinical studies. The rosettes formation test only detects the presence of sensitized cells. These cells have immunoglobulins at their surface. When brought into contact with red cells coated with the antigen, the red cells will form a ringlet or rosette around the sensitized lymphocytes.

A more specific test of cellular immunity is the leukocyte migration test (LMT) based on the principle that sensitized T lymphocytes, when in contact with the sensitizing factor, secrete a polypeptide that inhibits the migration of guinea pig macrophages and also of human leukocytes.

Normal migration of leukocytes in a migration chamber is markedly reduced when




FIG. 4. Migration index (surface with antigen/surface without antigen) in normal and thyroid patients; the antigen used is thyroglobulin (From Delespesse et al., 1973, by courtesy).

antigen to which the cells are sensitized is added to the medium. Results of the test are easily expressed as a migration index, as seen in Figure 4 comparing results of normal controls and patients affected with various thyroid diseases: a group of the latter display definite reactions against thyroglobulin.

The third test, admitted as specific of cell-mediated immunity, is the lymphoblast transformation test (LTT). When lymphocytes of a subject sensitized to a given antigen are cultured in the presence of this antigen, lymphoblastic transformation is induced. This can be studied by the morphological changes, for instance the number of mitoses, or by the measurement of the tritiated thymidine incorporated into the lymphocytes culture.

With these new concepts in mind and techniques at hand we can turn back to our problem, the study of autoimmunity in diabetes.

THE STUDY OF AUTOIMMUNITY IN DIABETES

As recalled earlier, clear-cut autoimmune diseases like lymphocytic thyroiditis have definite clinical, biological, serological and epidemiological characteristics. At first sight diabetes mellitus responds to these criteria. However, on a closer look, discrepancies become apparent (Table 6).

The clinical characteristics of autoimmune diseases (age and sex incidence) are found only in the adult-onset type: no other signs of immune abnormality can be detected in this form of diabetes except for the possibility of an immune complex disease and the association with other so-called idiopathic autoimmune conditions. It is clear that the immune complexes formed in insulin-treated patients are related to exogenous insulin and that deposition of this material in the capillary walls is by no means a true autoimmune process. As to the association of diabetes with other autoimmune conditions, we shall